buspirone has been researched along with Sexual Dysfunctions, Psychological in 12 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Sexual Dysfunctions, Psychological: Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed." | 4.91 | Advances in pharmacotherapy for treating female sexual dysfunction. ( Cucinella, L; Nappi, RE, 2015) |
| "T + S and T + B are well tolerated and safe and significantly increase the number of SSEs in different FSIAD subgroups." | 2.87 | Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials. ( Bloemers, J; Böcker, KBE; de Lange, RPJ; de Leede, L; Derogatis, LR; Eisenegger, C; Everaerd, W; Frijlink, HW; Gerritsen, J; Höhle, D; Kessels, R; Kingsberg, S; Koppeschaar, HPF; Olivier, B; Pfaus, JG; Tuiten, A; van Honk, J; van Rooij, K, 2018) |
| " In an explorative, randomized, double-blind, placebo-controlled, crossover study we investigated the possible effects of sublingual testosterone combined with a serotonin (5-HT)1A receptor agonist, and of sublingual testosterone combined with a phosphodiesterase type 5 inhibitor (PDE5-i) on sexual functioning in women with SSRI-induced sexual dysfunction." | 2.80 | Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study. ( Bloemers, J; Goldstein, A; Koppeschaar, H; Olivier, B; Poels, S; Tuiten, A; van Rooij, K; Worst, P, 2015) |
| "To investigate if treatment with a single dosage of T+5-HT(1A)ra will produce improvement in sexual functioning in women with Hypoactive Sexual Desire Disorder (HSDD) as the result of dysfunctional high sexual inhibition." | 2.78 | Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. ( Bloemers, J; Chivers, M; Everaerd, W; Gerritsen, J; Goldstein, I; Koppeschaar, H; Olivier, B; Poels, S; Tuiten, A; van Ham, D; van Mameren, F; van Rooij, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuiten, A | 4 |
| van Rooij, K | 4 |
| Bloemers, J | 4 |
| Eisenegger, C | 1 |
| van Honk, J | 1 |
| Kessels, R | 1 |
| Kingsberg, S | 1 |
| Derogatis, LR | 1 |
| de Leede, L | 2 |
| Gerritsen, J | 3 |
| Koppeschaar, HPF | 1 |
| Olivier, B | 3 |
| Everaerd, W | 3 |
| Frijlink, HW | 1 |
| Höhle, D | 1 |
| de Lange, RPJ | 1 |
| Böcker, KBE | 1 |
| Pfaus, JG | 1 |
| Leusink, P | 1 |
| Boeke, AJ | 1 |
| Laan, E | 1 |
| Poels, S | 3 |
| van Ham, D | 2 |
| Worst, P | 1 |
| Koppeschaar, H | 2 |
| Goldstein, A | 1 |
| Nappi, RE | 1 |
| Cucinella, L | 1 |
| Goldstein, I | 1 |
| van Mameren, F | 1 |
| Chivers, M | 1 |
| Landén, M | 2 |
| Högberg, P | 1 |
| Thase, ME | 1 |
| Eriksson, E | 1 |
| Agren, H | 1 |
| Fahlén, T | 1 |
| Michelson, D | 1 |
| Bancroft, J | 1 |
| Targum, S | 1 |
| Kim, Y | 1 |
| Tepner, R | 1 |
| Terao, T | 1 |
| Zajecka, J | 1 |
| Othmer, E | 1 |
| Othmer, SC | 1 |
2 reviews available for buspirone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
Advances in pharmacotherapy for treating female sexual dysfunction.
Topics: Buspirone; Clinical Trials, Phase III as Topic; Estrogens; Female; Humans; Menopause; Norpregnenes; | 2015 |
Strategies for the treatment of antidepressant-related sexual dysfunction.
Topics: Antidepressive Agents; Bupropion; Buspirone; Central Nervous System Stimulants; Depressive Disorder; | 2001 |
6 trials available for buspirone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.
Topics: Adult; Aged; Arousal; Buspirone; Cues; Double-Blind Method; Female; Humans; Inhibition, Psychologica | 2018 |
Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study.
Topics: Administration, Sublingual; Adult; Buspirone; Cross-Over Studies; Dose-Response Relationship, Drug; | 2015 |
Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.
Topics: Adult; Androgens; Buspirone; Cognition; Cross-Over Studies; Cues; Double-Blind Method; Drug Therapy, | 2013 |
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Topics: Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; F | 2005 |
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Dis | 1999 |
Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.
Topics: Adult; Amantadine; Anxiety Disorders; Buspirone; Depressive Disorder; Dopamine Agents; Female; Fluox | 2000 |
4 other studies available for buspirone and Sexual Dysfunctions, Psychological
| Article | Year |
|---|---|
Toward personalized sexual medicine: where is the evidence?
Topics: Androgens; Animals; Buspirone; Female; Humans; Phosphodiesterase 5 Inhibitors; Piperazines; Serotoni | 2014 |
Response to "toward personalized sexual medicine: where is the evidence?".
Topics: Androgens; Animals; Buspirone; Female; Humans; Phosphodiesterase 5 Inhibitors; Piperazines; Serotoni | 2014 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combina | 2001 |
Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Female; Humans; Male; Personality Inventor | 1987 |